Objective: To systematically analyze whether COVID-19 vaccination increases the risk of lymphoma. Methods: Data were retrieved from five databases, including PubMed, BMJ, Web of Science, Cochrane Library, and CDC (Centers for Disease Control and Prevention). Comprehensive searches of relevant articles in the databases were conducted to enhance search accuracy. Articles and references were further screened to improve retrieval precision. Data extraction and analysis were subsequently performed. Results: A total of 143 cases of post-COVID-19 vaccination lymphoma were identified, including 11 cases from 9 articles and 132 cases of vaccine adverse events. Systemic analysis revealed that among the cases, 53.8% were female, with a median age of onset at 62 years (range: 9-99 years). The most commonly implicated COVID-19 vaccines were mRNA vaccines, with Pfizer-BioNTech accounting for 51.7% and Moderna for 42.7%. Adenovirus vector vaccines, including ChAdOx1 nCoV-19 (0.7%) and vAd26.COV2.S (4.2%), were the next most prevalent. Approximately 45.7% of patients developed lymphoma within 30 days of vaccine administration. Non-Hodgkin lymphoma constituted the majority of pathological types (71.3%). Conclusion: The administration of the COVID-19 vaccine may potentially elevate the associated risk of lymphoma incidence.